FindTrial
Sign In

Recombinant Human Interleukin-2

DRUG3 trials

Sponsors

Yi Miao, Immatics US, Inc., Celularity Incorporated

Conditions

Bowel CancerCancerEsophageal CancerGallbladder CancerGastric CancerLiver CancerMetastatic HER2 Positive Gastroesophageal Junction CancerPancreatic Cancer

Phase 1

T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
NCT02662348
Yi MiaoBowel Cancer, Esophageal Cancer, Gallbladder Cancer +3
Start: 2016-02-29End: 2017-11-30Target: 6Updated: 2016-01-25
ACTolog in Patients With Solid Cancers
CompletedNCT02876510
Immatics US, Inc.Cancer, Solid Tumor
Start: 2017-06-30End: 2021-09-22Updated: 2025-02-04
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
TerminatedNCT05207722
Celularity IncorporatedMetastatic HER2 Positive Gastroesophageal Junction Cancer
Start: 2022-04-14End: 2024-02-15Updated: 2024-12-12

Related Papers

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Cancer Immunology Research2023-05-1213 citations
A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Journal of Clinical Oncology2023-01-242 citations
293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101)
Regular and Young Investigator Award Abstracts2020-11-012 citations
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers
Annals of Oncology2018-10-011 citations
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.
Journal of Clinical Oncology2018-05-20
Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for Patient and Personalized Target Selection
PROTEOMICS2018-03-0541 citations
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.
Journal of Clinical Oncology2018-02-101 citations